Fragile X syndrome

  • AUT00206, a Kv3 channel modulator with potential for the treatment of Fragile X Syndrome
    Fragile X conference, 2017

    Download poster (372 kB)

Epilepsy & Neurodevelopmental Disorders

  • Causal mutations in the genes encoding Kv3.1 and Kv3.2 have been increasingly linked to debilitating CNS diseases such as epilepsy, developmental encephalopathies, intellectual disability and autism

    Gunthorpe,

    Nature Communications, 2022

    Download publication (895 kb)

  • Kv3 6 offers potential as a precision medicine approach for the treatment of progressive myoclonic epilepsy (EPM7)Modulator AUT0020

    Feng et al

    Cell Reports Medicine, 2024

    Download publication (6MB)

Stroke

  • Kv3 Modulator AUT00201 can promote recovery post CNS trauma such as stroke via enhanced activity of parvalbumin interneurones

    Okabe et al

    Nature Communications, 2025

    Download publication (8MB)

Hearing Disorders

  • Impact of Kv3 Channel Modulator AUT3 on Auditory Temporal Resolution in Rats
    ARO Annual Meeting (22-26 February 2014)
    Rybal ko et al

    Download Abstract (37 kB)

  • AUT3, a Kv3 channel modulator, counteracts elevation of spontaneous firing rates in the auditory midbrain following noise trauma
    Society for Neuroscience Annual Meeting (9-13 November 2013)​
    Hesse et al

    Download Abstract (20.7 kB)

  • AUT3, a Kv3.1 positive modulator, suppresses chronic noise-induced tinnitus in a rat model​
    Tinnitus Research Initiative Conference (15-18 May 2013)
    Turner et al

    Download Abstract (43 kB)

  • Impact of Kv3 Channel Modulator AUT3 on In Vivo Auditory Processing in Mice
    ARO Annual Meeting (16-20 February 2013)
    Hesse et al

    Download Abstract (69.5 kB)

Schizophrenia

  • Autifony and collaborators publish the results from a clinical trial of AUT00206 in patients with schizophrenia

    Kaar SJ, Angelescu I, Nour MM, Marques TR, Sharman A, Sajjala A, Hutchison J, McGuire P, Large C, Howes OD. The effects of AUT00206, a novel Kv3.1/3.2 potassium channel modulator, on task-based reward system activation: a test of mechanism in schizophrenia. Psychopharmacology (Berl). 2022 Oct;239(10):3313-3323. doi: 10.1007/s00213-022-06216-3. Epub 2022 Sep 12. PMID: 36094619; PMCID: PMC9481488.

    Download Presentation (2.4 MB)

  • Angelescu I, Kaar SJ, Marques TR, et al. The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia. Journal of Psychopharmacology. 2022;36(9):1061-1069. doi:10.1177/02698811221122031

  • AUT00206, a Novel Kv3.1/3.2 Positive Modulator, Normalizes Gamma Oscillations in Patients with Schizophrenia
    SIRS Pharma Pipeline, April 2022

    Ben Mabrouk et al

    Download Abstract (15.9 kB)

  • AUT00206, a Novel Kv3.1/3.2 Positive Modulator, Normalizes Gamma Oscillations in Patients with Schizophrenia
    SIRS Pharma Pipeline, April 2022

    Download Presentation (4 MB)

  • AUT00206, a Novel Kv3.1/3.2 Positive Modulator, Normalizes Gamma Oscillations in Patients with Schizophrenia
    Schizophrenia International Research Society (SIRS) meeting, 2022
    Large et al

    Download Poster (3.2 MB)

  • AUT00206, a Novel Treatment for Schizophrenia, Improves Auditory Mismatch Negativity and Hearing Performance in Patients
    SIRS, April 2021

    Download Presentation (2.4 MB)

  • AUT00206, a Novel Treatment for Schizophrenia, Improves Auditory Mismatch Negativity and Hearing Performance in Patients
    SIRS, 2021
    Kaar et al

    Download Poster (2.2 MB)

  • Improvement in Otoacoustic Emissions and Speech-in-Noise Performance Among Patients with Schizophrenia treated with AUT00206
    ARO, 2021
    Sanchez et al

    Download Poster (311 kB)

  • AUT00206, a novel Kv3 channel modulator, reduces ketamine-induced BOLD signalling in healthy male volunteers: a randomised placebo-controlled crossover trial
    SIRS, 2019
    Deakin et al

    Download Poster (1.5 MB)

  • Early clinical evaluation of AUT00206, a novel and selective Kv3 channel modulator for the treatment of schizophrenia.
    ACNP, 2016
    Hutchison et al

    Download Abstract (127 kB)

  • In vitro evaluation of AUT00206, a novel and selective Kv3 channel modulator for the treatment of schizophrenia
    ACNP, 2016
    Hutchison et al

    Download poster (888 kB)

  • Early clinical evaluation of AUT00206, a novel and selective Kv3 channel modulator for the treatment of schizophrenia
    ACNP, 2016

    Download Poster (1.2 MB)

  • AUT00206 restores cognitive function in an animal model in 2 tasks in the presence of antipsychotic drugs.
    ACNP, 2016
    Neill et al

    Download Poster (1 MB)

  • A novel Kv3 positive modulator augments gamma frequency oscillations in the mammalian neocortex in vitro
    4th Biennial Schizophrenia International Research Conference (5-9 April 2014)
    Ben Mabrouk et al

    Download Abstract (15.9 kB)

  • Efficacy and relevance of the modulation of Kv3 channels to alleviate cognitive dysfunction in an animal model of schizophrenia symptomatology
    4th Biennial Schizophrenia International Research Conference (5-9 April 2014)
    Harte et al

    Download Abstract (25.6 kB)

  • Two novel KV3 ion channel modulators alleviate cognitive dysfunction and social behaviour deficits of relevance to schizophrenia in an animal model
    4th Biennial Schizophrenia International Research Conference (5-9 April 2014)
    Leger et al

    Download Abstract (24.9 kB)

  • Pharmacological activators and inhibitors of Kv3.1 potassium currents
    Society for Neuroscience Annual Meeting (9-13 November 2013)
    Brown et al

    Download Abstract (64.6 kB)

  • A novel Kv3 ion channel modulator restores cognitive function in an animal model of cognitive impairment in schizophrenia
    European College of Neuropsychopharmacology conference (18 October 2013)
    Neill et al

    Download Abstract (20.7 kB)

  • Pharmacological activators and inhibitors of Kv3.1 potassium currents
    ARO Annual Meeting (16-20 February 2013)
    Brown et al

    Download Abstract (30.5 kB)

  • Potential anti-manic efficacy of a Kv3 channel modulator in a model of amphetamine-induced hyperactivity and in CLOCKΔ19 mutant mice
    Society for Neuroscience Annual Meeting (13-17 October 2012)
    Sidor et al

    Download Abstract (56.1 kB)

  • Pharmacological modulation of Kv3 potassium channels regulates the firing of parvalbumin-positive cortical interneurons
    Society for Neuroscience Annual Meeting (13-17 October 2012)
    Large et al

    Download Abstract (17.7 kB)

  • Pharmacological modulation of Kv3.1 potassium currents
    Society for Neuroscience Annual Meeting (13-17 October 2012)
    Brown et al

    Download Abstract (64.6 kB)

Filter